EMEA-001776-PIP02-17-M01
Key facts
Invented name |
Skyrizi
|
Active substance |
Risankizumab
|
Therapeutic area |
Immunology-Rheumatology-Transplantation
|
Decision number |
P/0039/2021
|
PIP number |
EMEA-001776-PIP02-17-M01
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondylarthritis and juvenile idiopathic arthritis)
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
AbbVie Ltd
E-mail: paediatricteam@abbvie.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|